Author Archives: Bruno Quinney

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

This week in Drug Discovery (1 – 5 December) 

News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases.  The… Read More

#News

#Biotech #Laboratoires Théa #Opthalmology

Biotech partnership to advance retinal drug pipeline 

Biotechnology company Iolyx Therapeutics has entered a strategic development and commercialisation agreement with ophthalmic specialty company Laboratoires Théa to advance its retinal pipeline.  Under the license and development agreement, Iolyx has granted Théa exclusive worldwide development and commercialisation rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases.   Iolyx will receive up to… Read More

#Business & Investment #News

Colorectal cancer cells
#Clinical trial #Colorectal cancer #Larkspur Biosciences

First volunteers dosed in colorectal cancer trial 

Biotechnology company Larkspur Biosciences has dosed the first volunteers in the Phase I study of its treatment for microsatellite stable (MSS), colorectal cancer (CRC) and other solid tumours.  LRK-4189 is an oral, first-in-class targeted protein degrader of the lipid kinase PIP4K2C. The drug triggers multiple killing mechanisms… Read More

#News

#AlzeCure Pharma #Alzheimer's #Clinical trial

AlzeCure receives €2.5 million to advance Alzheimer’s drug 

Pharmaceutical company AlzeCure has received a €2.5 million grant from the European Innovation Council (EIC) to advance the Phase II trial of an Alzheimer’s disease treatment.  AlzeCure will advance the candidate NeuroRestore ACD856 to a Phase II trial, developed to improve patients’ learning and memory function and affect the course of disease in Alzheimer’s.   ACD856… Read More

#Business & Investment #News

Scientist in laboratory
#BioIndustry Association #Rare diseases #UK

Reform needed to give patients rare disease medicines 

The BioIndustry Association (BIA) has called for a new, reformed pathway to give UK patients access to innovative rare disease medicines.   According to the BIA’s new report, while the UK’s rare disease ecosystem has a solid foundation, more work is needed to build a connected, flexible and risk-proportionate access pathway to… Read More

#News

#Actithera #AstraZeneca #Radiopharmaceuticals

Actithera appoints new CMO to advance radiopharmaceuticals 

Radiopharmaceutical biotech company Actithera has appointed Darshan Dalal as Chief Medical Officer.  Dalal will lead the clinical strategy and build the clinical development organisation as Actithera advances its lead fibroblast activation protein (FAP)-targeting RLT into the clinic. The company is also building its pipeline of differentiated precision-engineered radiopharmaceuticals.  Dalal… Read More

#News

Peptide
#AltPep Corporation #Alzheimer's #Neurodegenerative disorders #Peptides

Custom-designed peptide could treat Alzheimer’s 

New findings show a custom-designed peptide has promising potential as a treatment for early Alzheimer’s disease (AD).  The candidate SOBIN-AD, developed by biotechnology company AltPep Corporation, demonstrated potential to improve cognition both before and after the onset of cognitive impairment in pre-clinical trial. SOBIN-AD also reduced Aβ… Read More

#News

#Biotech #Financing #TRIMTECH Therapeutics

TRIMTECH Therapeutics appoints new Chair of the Board 

Biotechnology company TRIMTECH Therapeutics has appointed Alison Lawton as Chair of the Board as the company moves to advance its portfolio of disease-modifying therapies.  Lawton arrives at TRIMTECH with more than 35 years of global pharma and biotech leadership expertise, leading global regulatory strategy for numerous product approvals and gaining extensive… Read More

#News

Quantum computing
#Artificial intelligence (AI) #Biotech #Life sciences #Quantum computing

Quantum-biotech partnership to develop next-gen therapeutics  

Quantum company IonQ has partnered with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutics using hybrid quantum and quantum-AI technologies.  The collaboration will initially focus on areas including bioprocess optimisation, disease-modelling workflows, and quantum-enhanced simulation to support the design and manufacturing of advanced therapies. By bringing together CCRM’s expertise in… Read More

#Business & Investment #News

Alzheimer's disease drug
#Alzheimer's #Clinical trial #Neurodegenerative disorders

Novel therapeutic could treat neurodegenerative diseases 

A novel therapeutic could improve memory, cognitive function and neuroinflammation in neurodegenerative diseases.  VNA-318, developed by biotechnology company Vandria, was tested in preclinical mouse models of neurodegeneration and cognitive impairment. Data shows the candidate created an immediate improvement in memory, learning and cognitive function, as well… Read More

#News

Male patient with doctor
#Archeus Technologies #Clinical trial #Prostate cancer #Radiopharmaceuticals

First patient dosed in Phase I trial of prostate cancer drug 

The first patient has been dosed in the Phase I clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC).  ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy targets prostate-specific membrane antigen (PSMA) and,… Read More

#Cancer Research #News

#Awards #Drug discovery #Metabolomics

$30,000 award up for grabs in metabolomics research 

Biotechnology company NADMED has launched an award worth $30,000 to accelerate breakthroughs in metabolomics research.  The NADMED Award 2026 is a global initiative designed to empower scientific discovery in redox biology and accelerate innovation across medicine, life sciences, and biotechnology. The award aims to enable scientists and clinicians… Read More

#News

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug development #NHS

eXmoor and NHS trust partner on cell & gene therapies 

Cell and gene therapy CDMO eXmoor Pharma has partnered with Royal Free London NHS Foundation Trust to collaborate on the development and manufacturing of cell and gene therapies in the UK. The collaboration brings together eXmoor’s later-phase clinical manufacturing capabilities  with the trust’s Cell and Vector Innovation Centre (CVIC), which has early-phase clinical manufacturing expertise. The organisations… Read More

#Business & Investment #News

#Cancer research #Citius Pharmaceuticals #Immunotherapy #Lymphoma

Citius Oncology launches immunotherapy treatment in US 

Citius Oncology has announced the US commercial launch of Lymphir, its novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL).  The launch follows approval by the US Food and Drug Administration (FDA) in August 2024 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).  The FDA approval was… Read More

#News #Regulatory

Protesting against health inequalities
#ABPI #NHS #UK government #US government

UK-US trade deal good news for UK life sciences, ABPI says 

The UK-US trade agreement is good news for NHS patients and will support the UK life sciences industry, the Association of the British Pharmaceutical Industry (ABPI) says.  The agreement will ensure that UK pharmaceutical exports to the US continue to face 0% tariffs for three years. In… Read More

#News